Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in ...

Eli Lilly has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kisunla (donanemab-azbt) ...

Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...

Report Ocean has released a market research report on the Alport Syndrome Treatment industry, covering 150+ countries and analyzing over 1,00000 published and forthcoming reports per year. The report, ...

Eli Lilly's Kisunla receives Japanese approval for the treatment of early symptomatic Alzheimer's disease: Indianapolis Wednesday, September 25, 2024, 09:00 Hrs [IST] The Ministry ...

Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.

Abuse-deterrent transdermal technology can be used to prevent the misuse of drugs with abuse potential, such as fentanyl, by incorporating aversive agents into transdermal patches. Abuse-deterrent ...

Seemingly overnight, Arizona has emerged as a big player in the rejuvenated U.S. semiconductor industry, What does that mean, ...

Telix has paid an upfront cost of $230m to acquire 31 licenced radiopharmacies from RLS located across the US.

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...

Prime Minister Narendra Modi on Tuesday shared highlights of his very intense visit to the United States, saying it has been ...

Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer - - ...